抗纤维化治疗下特发性肺纤维化的疾病进展。

IF 1.4 4区医学 Q4 RESPIRATORY SYSTEM

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases Pub Date : 2023-09-13 DOI:10.36141/svdld.v40i3.14048

Aykut Cilli, Fatih Uzer

{"title":"抗纤维化治疗下特发性肺纤维化的疾病进展。","authors":"Aykut Cilli, Fatih Uzer","doi":"10.36141/svdld.v40i3.14048","DOIUrl":null,"url":null,"abstract":"Idiopathic pulmonary fibrosis (IPF) is the most common progressive interstitial disease of unknown etiology. The course of disease is not possible to predict. Frequent monitoring using multiple assessments is important to evaluate disease progression. Currently, there is no consensus on how progression should be defined. Nintedanib and pirfenidone slow the progression of IPF, but the disease can progress even under anti-fibrotic treatment. The goal of this review is to examine and summarize the current data about IPF progression in patients who were on anti-fibrotic treatment. Also, we outline the limitations of the tests used for disease progression.","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/da/SVDLD-40-34.PMC10540722.pdf","citationCount":"1","resultStr":"{\"title\":\"Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment.\",\"authors\":\"Aykut Cilli, Fatih Uzer\",\"doi\":\"10.36141/svdld.v40i3.14048\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Idiopathic pulmonary fibrosis (IPF) is the most common progressive interstitial disease of unknown etiology. The course of disease is not possible to predict. Frequent monitoring using multiple assessments is important to evaluate disease progression. Currently, there is no consensus on how progression should be defined. Nintedanib and pirfenidone slow the progression of IPF, but the disease can progress even under anti-fibrotic treatment. The goal of this review is to examine and summarize the current data about IPF progression in patients who were on anti-fibrotic treatment. Also, we outline the limitations of the tests used for disease progression.\",\"PeriodicalId\":21394,\"journal\":{\"name\":\"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/da/SVDLD-40-34.PMC10540722.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.36141/svdld.v40i3.14048\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36141/svdld.v40i3.14048","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 1

摘要

特发性肺纤维化（IPF）是最常见的进行性间质性疾病，病因不明。疾病的进程无法预测。使用多种评估进行频繁监测对于评估疾病进展非常重要。目前，对于如何定义进展还没有达成共识。宁替达尼和吡非尼酮可以减缓IPF的进展，但即使在抗纤维化治疗下，这种疾病也可以进展。这篇综述的目的是检查和总结正在接受抗纤维化治疗的患者的IPF进展的最新数据。此外，我们还概述了用于疾病进展的测试的局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment.

Idiopathic pulmonary fibrosis (IPF) is the most common progressive interstitial disease of unknown etiology. The course of disease is not possible to predict. Frequent monitoring using multiple assessments is important to evaluate disease progression. Currently, there is no consensus on how progression should be defined. Nintedanib and pirfenidone slow the progression of IPF, but the disease can progress even under anti-fibrotic treatment. The goal of this review is to examine and summarize the current data about IPF progression in patients who were on anti-fibrotic treatment. Also, we outline the limitations of the tests used for disease progression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 医学-呼吸系统

CiteScore

2.20

自引率

6.20%

发文量

期刊介绍： Sarcoidosis Vasculitis and Diffuse Lung Disease is a quarterly journal founded in 1984 by G. Rizzato. Now directed by R. Baughman (Cincinnati), P. Rottoli (Siena) and S. Tomassetti (Forlì), is the oldest and most prestigious Italian journal in such field.